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Abstract 
Aims In the Oslo study of 1972-3 we compared the mortality pattern up to 40 years in cardiovascular 
healthy groups at supposedly high and low risk and some groups having cardiovascular disease at 
screening. 
Methods At screening 16203 (63 % of invited) men aged 40-49 years participated. Groups were 
identified by means of questionnaires regarding diseases, measurements of total cholesterol, 
triglycerides, glucose and blood pressure. Six groups were identified: very high cholesterol, very high 
blood pressure, very high glucose, non-smoking with non-elevated such risk factors, a randomized 
diet and antismoking trial, and a randomized drug treatment in mild to moderate hypertension.. Cox 
regression analysis with Kaplan-Meier graphs was used for statistical analyses. 
Results The supposedly low risk group had total mortality of one third as compared to other groups 
such as men with hypertension, diabetes, hypercholesterolemia or those who participated in the two 
trials. Between these latter groups 2-5 years differences in median survival time were found, but their 
absolute risk stayed at rather high levels through all years with median remaining lifetime 3-8 years 
shorter than men free of known cardiovascular disease, diabetes or hypertension. 
Conclusions The long term preventive effects on total mortality seems large if the levels of the 
classical risk factors blood pressure, total cholesterol and glucose can be adequately controlled 
concurrently with a non-smoking behavior. The study indicated that non-smoking and low total 
cholesterol were the most important contributors to extended survival. 
 
Word count: 250 
 
Keywords: long term mortality; risk factors; prevention 
 
3 
 
Introduction 
In 1972-3 a cardiovascular study (CVD) in Oslo took place that was the first in a series of similar 
studies performed by the National Health Service in different counties of Norway [1]. Repeated 
screenings were performed by the years and the analyses of the collected data have provided much 
knowledge of CVD epidemiologic in the Norwegian population [2-9]. 
Since the second world war myocardial infarction (MI) incidence and mortality had increased at all 
years and had reached epidemic proportions, so prevention strategies were highly needed. Among 
several purposes of the Oslo study screening was the recruitment of participants to two randomized 
controlled trials among supposedly healthy men with a high risk of developing CVD. During the 
screening and two reexaminations to include men with no cardiovascular disease to the two trials, one 
diet and antismoking trial and one drug trial in mild hypertension [10-11], several other groups 
supposedly at both low and high risk were pre specified.  These were participants with hypertension 
and hypercholesterolemia with levels above those selected for the trials, newly detected diabetics and 
a non-smoking group with simultaneously lower levels of the classical risk factors. Since then levels 
of classical risk factors have been drastically reduced, current smoking prevalence has decreased to 
less than a half, more effective drug treatment both for hypertension and hypercholesterolemia has 
been documented as well as better treatment and procedures in secondary prevention. At the same 
time large dietary changes have taken place with more sedentary behavior and a massive increase in 
body mass index. The prognosis of the pre specified groups from the Oslo study would therefore be 
hard to predict. Some men had also experienced a cardiovascular event or had diabetes at time of 
screening and their survivals have also remained unknown during these years. 
Thus, the purpose of this study was to report the long-term survival results in the predefined 
subgroups as well as the diseased groups during an almost 40 year time period. 
 
Material and methods 
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In 1972-3 all men born 1923-1932 in Oslo were invited to a screening examination for CVD. Eligible 
were 25915 men and 16203 participated (63 %) and they filled in a questionnaire about prevalent 
CVD and diabetes. Men without such diseases were called healthy in whom two reexaminations 
followed to include participants to the planned randomized trials [3]. In the mild hypertension trial 
men with blood pressure 150-179/95-109 mmHg were included whereas men with total cholesterol 
6.4-8.9 mmol/L were included into the diet and antismoking trial provided they had a coronary risk 
score in the upper quartile in a risk score distribution based on the three classical risk factors systolic 
blood pressure, total cholesterol and cigarette smoking [3]. An assumed low risk group consisted of 
men with total cholesterol at screening (Liebermann Burchart method) <6.0 mmol/L, <6.0 mmol/L 
fasting at the first reexamination and with blood pressure <145/95 mmHg at both investigations and 
they should not have smoked cigarettes or be currently smoking pipe or cigar. Finally, fasting 
triglycerides should be <4.0 mmol/L and fasting blood sugar <9.5 mmol/L. The intention was to 
include 500 participants to this group, but ended up with 367 due to lower participation proportion 
than anticipated.  
Men with a higher blood pressure than those included in the mild hypertension trial (high blood 
pressure group) were referred to specialized hypertension clinics, as were men with higher total 
cholesterol than those in the diet and antismoking trial (high cholesterol group). The same took place 
for those with a fasting glucose above 9.5 mmol/L (newly detected diabetes). The two randomized 
trials have been followed up with respect to morbidity and mortality up to 10 years for mild 
hypertension trial [12] and 20 years in the diet and antismoking trial [13]. Separate reports with 
mortality results by intervention/treatment group up to 40 years are planned for publication. Thus, 
there are 6 assumed healthy groups to be compared, one low risk group and 5 groups assumed to be at 
somewhat higher risk than the average screened population: the Mild hypertension trial, the Diet 
antismoking trial, the High blood pressure group, the High cholesterol group and the Newly detected 
diabetes group. 
 This follow up is extended to December 31th 2011 with respect to mortality. ICD code 410 was used 
for MI in version ICD8-9 and I21 in version ICD10. Statistics Norway added mortality data to the 
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Oslo study data file according to permissions given by the Data Inspectorate and tax authorities, 
Department of health and the project was approved by the regional ethics committee for medical 
research. 
Statistical methods 
Cox proportional hazards regression models were used and time to death or time to death at first MI 
was the dependent variable in some analyses and obtained age in others. Emigrated men were 
censored at date of emigration. The 6 risk group codes were exposure factors with the rest of men as 
reference , while adjustment factors were total cholesterol, systolic blood pressure, glucose and daily 
smoking (Yes,No). The reference group consists of all men except those in the 6 subgroups. They are 
a mixture of healthy and diseased men whose risk level in itself  is not of interest in this study.  When 
MI mortality was analyzed all other causes of death was used as a competing cause of death. The 
standard method used in STATA 13 was applied according to a method by Fine and Gray (14). A 
cumulative MI death incidence graph was also made by STATA 13 as were graphs of hazard 
functions by time. The cumulative incidence gives an approximation to the MI mortality probabilities. 
In our case with far more non-MI than MI deaths, the differences between competition adjusted or 
non-adjusted results will probably be rather great. 
To compare predictive ability of risk factors on total mortality log likelihood statistics were used. This 
contains all statistical information given the model. A full model with the 6 groups and the 4 classical 
risk factors was estimated and its log likelihood was calculated. Then, one at a time, each of the 4 
factors was removed from the model and rerun obtaining an updated log likelihood and the change for 
each factor was recorded. The factor with the greatest change would indicate the best predictive 
ability. 
Results 
Table I shows number of deaths  among men with MI, angina pectoris, hypertension and diabetes 
found at screening. In most categories mortality risk was higher than in the healthy group, but some 
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subjects may have had several categories of disease. The absolute risk of death or death at first MI 
were high in those who had developed MI prior to screening or had diabetes as compared to not. 
Figure I displays unadjusted Kaplan Meier survival curves for the healthy men and for those with MI, 
diabetes, or drug treated for hypertension. All groups had markedly reduced median survival time as 
compared to the healthy one, that had 35 years of median survival time after screening. Men with 
hypertension had 26 years median survival whereas diabetics and men with MI had only 19 years 
median survival. 
The low-risk group experienced an especially low risk of death at first MI with only 8 such deaths 
through 40 years of observation (Table II). Also total mortality was low as compared to other risk 
groups or the healthy subgroup, (Figures I and II). The low risk group had a median survival time of 
88 years and a total mortality of one third as compared to other groups such as men with hypertension, 
diabetes, hypercholesterolemia or those who participated in the two trials. Between these latter groups 
2-5 years differences in median survival time were found, but their absolute risk stayed at rather high 
levels through all years with median remaining lifetime 3-8 years shorter than men free of known 
cardiovascular disease, diabetes or hypertension. Between the 5 pre specified high risk groups there 
were only marginal total mortality risk differences, unadjusted for risk factors. This can also be seen 
from Figure III where smoothed hazard rates are displayed by time for each of the 6 risk groups. 
There is nothing to indicate that rates have developed differently by time, since an exponential 
increase seems to fit the data well in all groups.  
Table III shows hazard ratios for the 6 groups at risk versus reference adjusted for the 4 classical risk 
factors at the end of the table. Despite statistical significant differences in mortality to the reference 
group, differences were small between the 6 groups internally, as displayed in Figure IV (Online 
version). This indicates that the sole difference in mortality risk between the low risk group and the 5 
others was purely due to the measured differences in the 4 risk factor levels measured in 1972-73. 
These factors associated strongly to 40 year mortality, adjusted for each other.  
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A cumulative incidence function graph was made for death at first MI (Figure V, Online version), 
showing the unadjusted different survival patterns between the low and the other high-risk groups. In 
this curve non-MI deaths are treated as competing risks. After about 20 years of follow up there seems 
to be a break in the development of MI mortality risk, but since the model uses only one underlying 
hazard function, these changes seem to happen at the same time, which is probably not fully true. It 
should rather be interpreted that a shift in decline of MI mortality took place at some time during the 
1990s. The poorest survival had the newly detected diabetes group.  The low risk group still had the 
best survival, but differences to the other groups were moderate but still present. When adjustments 
were made for the 4 risk factors, there was no significant difference between any group as compared 
to reference (data not shown).  
The log likelihood analysis showed that smoking was by far the most predictive risk factor among the 
4 classical ones. When smoking was removed from the full model log likelihood was reduced by 
621.7 units, whereas this reduction was 205.1 for systolic blood pressure, 83.8 for total cholesterol 
and 59.0 for glucose. 
Discussion 
This is the first report of the long term prognosis of 6 pre specified groups at risk in the Oslo study in 
1972-73. The study validates the importance on mortality of classical risk factors measured at middle 
age through elderly and old age, despite drastic changes in risk factor distributions and treatment 
modalities introduced in Norway since that time. 
There was a high excess mortality in prevalent MI men in this study with a relative risk of 3.3 (2.8-
3.9), well known from previous studies among survivors from hospitalized acute MI patients [13], but 
is evidently also valid for patients with prevalent coronary heart disease. Due to the generally much 
better control of MI risk factors as well as a lower absolute risk to day together with improved 
treatment strategies of both acute MI as well as secondary prevention by potent drugs such as statins, 
it is not clear whether such findings will be valid in the future. Men with diabetes also had a clear 
excess mortality as compared to healthy men, HR= 2.9 (2.5-3.5) but treatment strategies have not 
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resulted in substantial risk reductions [15]. After 30 years of follow up 23 % were alive among the 
established diabetics, whereas this was 45 % for the newly detected ones. It could be that the latter 
group had had their diabetes for a shorter time resulting in somewhat longer survival. 
The low-risk group had very few deaths at first MI. The concept of selecting non-smoking men 
without high levels of classical risk factors proved to give low mortality risk both of MI and totally. 
The group results indicate the great prevention potential even on total mortality if levels of classical 
risk factors can be kept fairly low while avoiding the habit of smoking. This happened despite the 
great changes in life style and advancements in treatment and intervention procedures during these 
years. The main factor to combat is smoking since that factor damages many organ systems and 
showed up in the prognostic analyses to be a better predictor for total mortality than the others. Also 
the other factors have been influential since adjustments for them closed the gap between risk groups 
with regard to survival. 
In Norway massive reductions in total cholesterol (about 1 mmol/L in Norway), a more effective and 
metabolically neutral hypertension control and a more than 50 % reduction in smoking prevalence 
have together with more effective procedures and treatments of acute MI and better drugs in 
secondary prevention more or less eliminated coronary heart disease mortality at younger ages and 
substantially reduced it in the elderly. This has in all likelihood resulted considerably to the 
impressive fact that the average lifetime has increased by 1 year for every 5th running year during the 
latest 2-3 decades.  
 
Conclusions 
Large differences in long-term survival took place between groups in which classical risk factor levels 
differed. Today these are except for glucose regarded as causal by most researchers and the large 
reductions we have seen in cardiovascular and total mortality in the population as a whole during 
these 40 years are partly a result of the reduction on levels of these risk factors, mainly through life 
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style changes. At the same time modern drugs, such as metabolically neutral antihypertensive drugs 
and statins have been available to treat patients at high cardiovascular risk. Judging from Table3 and 
the observed large changes in smoking habits and total cholesterol  in Norway the greatest risk 
reductions are probably due to the massive reduction in smoking and the changes in total 
cholesterol. The large increase in BMI and diabetes in the population has so far not transferred into 
increased mortality at the population level. However, there are observations in Sweden and Finland 
that the cholesterol level is again increasing slightly, probably due to the big wave of protein-rich 
and fatty diets promoted by some to reduce BMI levels in the overweight and obese (16,17). If this 
trend gets massive it may announce a less beneficial development in CVD mortality trends in the 
years to come. 
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Tabell 1 First myocardial infarction and total death risk through 40 years in Oslo study for groups 
with prevalent diseases. 
Prevalent disease at 
screening 
MI 
deaths/Number 
screened (%) 
Total deaths (% of 
screened) 
  
Myocardial infarction 
Angina Pectoris 
Other heart disease 
60/164 (36.6) 
51/194 (26.3) 
21/191 (11.0) 
 
148 (92.5) 
170 (87.6) 
141 (73.8) 
 
  
AO 
Stroke 
Diabetes 
8/41 (19.5) 
6/36 (16.7) 
29/153 (19.3) 
 
34 (82.9) 
36 (100.0) 
141 (92.2) 
 
  
Treatment of 
hypertension 
82/446 (18.4) 
 
370 (83.0)   
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Healthy (without 
acknowledged CV 
disease) 
1250/15082 (8.3) 9379 (62.2) 
 
  
MI= myocardial infarction; CI= confidence interval; AO= atherosclerosis obliterance; CV= 
cardiovascular. 
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Table 2 Death at first myocardial infarction and total death proportion through 40 years in assumed 
healthy CVD high risk groups defined after screening reexaminations.                                  
Group MI 
deaths/Number 
at risk (%) 
 Number of 
deaths (%) 
 
Diet antismoking trial 
    Intervention + 
    Control   
 
139/1232 (11.3) 
 
  
880 (71.4) 
 
 
Mild hypertension trial 
    Drug Treatment + 
   Control 
   
 
102/785 (13.0) 
 
  
683 (87.0) 
 
 
Low risk  8/367 (2.2)  116 (31.6)  
High BP  
     
14/55 (25.5) 
 
 47 (85.5)  
High TC  
Newly detected diabetes  
28/168 (16.7) 
17/87 (19.5) 
 
 125 (74.4) 
69 (79.3) 
 
 
CVD= cardiovascular disease; MI= myocardial infarction; BP= blood pressure; TC= total cholesterol 
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Table 3 Hazard ratio of  40-year total mortality by 6 pre specified risk groups (vs all other 
participants) and classical risk factors based on 16195 men with complete data and 10222 
deaths. 
Group factor* Hazard Ratio 95 % CI P-value 
Mild hypertension trial 0.84 0.76-0.92 <0.001 
Diet antismoking trial 0.83 0.77-0.89 <0.001 
Low risk group 0.75 0.62-0.91 0.003 
High cholesterol group 0.74 0.55-1.00 0.047 
High blood pressure group. 0.69 0.57-0.84 <0.001 
Newly detected diabetes 
 
Risk factors§ 
0.91 0.70-1.19 0.500 
Total serum cholesterol 
(per 1mmol/L) 
2.59 2.24-3.00 <0.001 
Systolic blood pressure 
(per 1 mmHg) 
1.013 1.011-1.014 <0.001 
Serum glucose 
(per 1 mmol/L) 
Daily smoking (Yes/No) 
 
1.99 
 
2.07 
1.72-2.29 
 
1.95-2.25 
<0.001 
 
<0.001 
*Adjusted for total serum cholesterol, systolic blood pressure, serum glucose and daily smoking. 
§ Adjusted for each other.
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Figure 1 Kaplan Meier survival curves through 40 years for healthy men and men with prevalent 
myocardial infarction, diabetes and drug treated hypertension.   
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Figure 2 Kaplan Meier survival curves for 6 groups defined after first and second screening 
reexamination.
 
Figure 3 Smoothed hazard function of total mortality by risk groups and survival time.  
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